Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Chemotherapy in Newly Diagnosed AML
NCT04628026Phase 3Recruiting
- Sponsor
- Ulm University
- Start
- Sep 2022
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Ulm University. Primary endpoints: Event Free Survival at 16 months and Dose-limiting toxicities at day 42. Started Sep 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04628026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628026.